Lates News

According to the AI Newsletter of Meijing, Huayuan Securities released a research report on April 26, giving Yuandong Biology (688513.SH) a "buy" rating. The main reasons for the rating include: 1) The progress of the TPD field pipeline in clinical trials is actively advancing; 2) Important progress has been made in the research and development of small molecule innovative drugs and biologics; 3) The steady progress of the internationalization of raw material preparation, and the effectiveness of global layout is evident. (Daily Economic News)